CorMatrix Cor TRICUSPID ECM Valve Replacement Study

Tricuspid Valve Disease Clinical Trial

Official title:

CorMatrix Cor TRICUSPID ECM Valve Replacement Safety and Early Feasibility

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02397668
• Other study ID #: 14-PR-1101 Rev. L
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: December 15, 2024

Study information

• Verified date: January 2023
• Source: CorMatrix Cardiovascular, Inc.
• Contact: Robert G Matheny, MD
• Phone: 404-276-7777
• Email: rmatheny[@]cormatrix.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Pivotal Study of the Cor TRICUSPID ECM Valve (or Cor PEDIATRIC Tricuspid ECM Valve). This study follows the EFS and is now to determine the safety and efficacy of the Cormatrix Cor TRICUSPID Valve for any patients requiring surgical replacement of the tricuspid valve.

Description:

CorMatrix Cardiovascular, Inc. has developed a device for heart valve replacement, the CorMatrix® Cor ECM® Tricuspid Valve, which can be implanted to replace dysfunctional tricuspid heart valves. This Pivotal Study is being performed to verify the ability to successfully implant the Tricuspid Valve, the clinical safety of the device, and whether the device performs its intended use. The study is a multi-center, prospective, single-arm, Pivotal Study of subjects receiving the Cor TRICUSPID ECM Valve or Cor PEDIATRIC Tricuspid ECM Valve. The study will be conducted at up to 15 sites. Up to 60 subjects will undergo tricuspid valve replacement (TVR) with the CorMatrix ECM Valve for the surgical management of tricuspid valve disease. The cohort will include up to 60 adult and 18 pediatric patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 78
• Est. completion date: December 15, 2024
• Est. primary completion date: December 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 70 Years

Eligibility

Inclusion Criteria:

1. Patient with a regurgitant or absent tricuspid valve requiring surgical treatment including those patients having concomitant cardiac procedures

2. Male or female

3. Patient/authorized legal guardian understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent and the pediatric patient (if applicable) provides written assent (if able) prior to procedure

4. Patient/patient's authorized legal guardian is geographically stable (or willing to return for required study follow-up) and understands and is willing to fulfill all of the expected requirements of this clinical protocol

5. Children with congenital disease where the Cor PEDIATRIC Tricuspid ECM Valve would be the physiological right-sided valve

Exclusion Criteria:

1. Tricuspid annulus too small (< 10mm) to accommodate the Cor Tricuspid ECM Valve

2. Left ventricular ejection fraction (LVEF) < 25%

3. Mean pulmonary pressure > 50mm Hg or pulmonary vascular resistance greater than 6 Woods Units

4. Emergency cardiac procedure. An example would be a person requiring resuscitation and in cardiogenic shock. An unscheduled or unplanned emergency surgery

5. Cardiac transplant patient

6. Acute transmural myocardial infarction (MI) within 7 days of enrollment that results in cardiogenic shock

7. Patients with a single ventricle where the Cor Tricuspid ECM Valve would be the systemic AV valve

8. Documented primary coagulopathy or uncorrected platelet disorder, including thrombocytopenia (absolute platelet count <30k). Patient can be enrolled regardless of these parameters if in the opinion of the Investigating Surgeon the coagulopathy can be adequately reversed by transfusions. An example would be the reversal of thrombocytopenia by transfusion of platelets

9. Documented evidence of intrinsic hepatic disease (defined as liver enzyme values (aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin) that are > 5 times the upper limit of reference range within 30 days of enrollment, except in association with acute/reversible decompensation as determined by the Investigator)

10. Documented evidence of significant renal dysfunction (serum creatinine > 4.0mg/dl or GFR< 30 on the modified Schwartz formula)

11. Stroke within 30 days prior to enrollment

12. Major or progressive non-cardiac disease (liver failure, renal failure, cancer (CA)) that has a life expectancy of less than one year

13. Known cancer (cancer-free <1 year; does not include non-metastatic basal cell carcinoma or cervical carcinoma) and/or undergoing treatment including chemotherapy and radiotherapy

14. Hematological disorders (e.g., aplastic anemia) or patients taking bone marrow suppressant drugs

15. Known sensitivity to porcine materials

16. Contraindication to anticoagulation/antiplatelet therapy (aspirin (ASA) and/or Plavix)

17. Patients who are pregnant (method of assessment Investigator's discretion)

18. Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study, without CorMatrix written approval

Related Conditions & MeSH terms

• Tricuspid Valve Disease

Intervention

Device:
• CorMatrix Cor TRICUSPID ECM Valve
CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital	Cincinnati	Ohio
United States	St Francis Hospital	Indianapolis	Indiana
United States	Springhill Memorial Hospital	Mobile	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
CorMatrix Cardiovascular, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedural Success	Device Success and No TV device- or TV procedure-related SAE's	30 days postop
Secondary	Device Success	Patient alive with original intended CorMatrix ECM TV in place, No additional surgical or interventional procedures related to the TV, and Intended performance of the TV	30 day and all follow up time points
Secondary	Technical Success	Exit OR Alive, Successful implant of the single intended CorMatrix ECM TV, No need for additional emergency surgery or re-intervention related to the TV device, Final post-op TTE shows TR < moderate	within 24 hours